

Table S1. Detailed clinical information of each group in the present study

	NonConvVx (<i>n</i> = 10)	Conv6mVx1 (<i>n</i> = 10)	Conv6mVx2 (<i>n</i> = 5)	Conv18mVx1 (<i>n</i> = 18)	Conv18mVx2 (<i>n</i> = 10)
Age, years, median (range)	33 (25–47)	45 (27–63)	43 (27–63)	27 (20–47)	30 (22–51)
Male sex, <i>n</i> (%)	5 (50)	4 (40)	1 (20)	5 (28)	4 (40)
Vaccine type					
BNT162b2, <i>n</i> (%)	10 (100)	10 (100)	5 (100)	6 (33)	6 (60)
mRNA-1273, <i>n</i> (%)	0 (0)	0 (0)	0 (0)	12 (67)	4 (40)
Days from the diagnosis of COVID-19 to 1 st vaccination, median (IQR)	-	80 (45–146)	116 (51–176)	561 (558–570)	533 (529–539)
Days from vaccination to the sample collection, median (IQR)	NonConvVx1: 8 (7–10) NonConvVx2: 9 (8–9)	32 (13–43)	27 (21–28)	26 (17–28)	12 (7–19)

NonConvVx, the uninfected and vaccinated group; Conv6mVx1, vaccinated once within 6 months after COVID-19; Conv6mVx2, vaccinated twice within 6 months after COVID-19; Conv18mVx1, vaccinated once around 18 months after COVID-19; Conv18mVx2, vaccinated twice after 18 months around COVID-19; IQR, interquartile range